JPRN-UMIN000032843招募中未知
Efficacy of Alirocumab in the arteriosclerotic biomarker changes after percutaneous coronary angioplasty (PCI). - Efficacy of Alirocumab in the arteriosclerotic biomarker changes after percutaneous coronary angioplasty (PCI).
Department of Cardiovascular Medicine, Faculty of Medical Sciences, University of Fukui0 个研究点目标入组 50 人开始时间: 2018年6月2日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •-HMG-CoA reductase inhibitor is not used at the time of introduction -At the time of introduction of research drugs, patients with LDL-C less than 100 mg / dL -Contraindicated patients with HMG-CoA reductase inhibitors -Hypersensitivity to the study drug
研究者
相似试验
Unknown
4 期
Assessment of Atherosclerotic Plaque Characteristics Change by DCE-MRI With AlirocumabAtherosclerosisHyperlipidemiaNCT02992301Westside Medical Associates of Los Angeles35
进行中（未招募）
1 期
Effect of Sarilumab on atherosclerotic disease in Rheumatoid ArthritisRHEUMATOID ARTHRITISMedDRA version: 21.0Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2019-004078-24-ESIDIVA20
招募中
不适用
Efficacy of Evolocumab in patients with arteriosclerosis obliterans.arteriosclerosis obliteransJPRN-UMIN000032844Department of Cardiovascular Medicine, Faculty of Medical Sciences, University of Fukui20
已完成
不适用
Efficacy of Alirocumab for Thin-cap fibroatheroma in patients with coronary artery disease estImated by optical coherence tomography trial.vulnerable plaque in patients with coronary artery diseaseJPRN-UMIN000029533Kobe University Graduate School of Medicine24
已完成
2 期
Effect of Alirocumab on Lipoprotein(a) (Lp(a)) Metabolism in Subjects with Moderate to High Risk of Heart DiseaseCardiovascular Disease (CVD)Cardiovascular - Coronary heart diseaseACTRN12617000401358inear Clinical Research Ltd.21